Galapagos Phase 1/2 CAR-T trial continues to show strong outcomes in r/r NHL
Galapagos presented updated data from the phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) in r/r NHL, which came in line with the previously released abstract. We continue to see strong outcomes and note that the 7 day vein to vein time was achieved in 43/47 patients, demonstrating the feasibility of the company's de-centralised manufacturing process in a larger set of patients. In our view, this further de-risks the NHL program, and we look forward to the US portion of the trial which was due to begin recruitment before YE24. We reiterate our € 50 TP and BUY rating.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.